Pathfinder Cell Therapy, Inc.
PFND · OTC
9/30/2015 | 6/30/2015 | 3/31/2015 | 12/31/2014 | |
|---|---|---|---|---|
| Market Cap | $5,337 | $2,869 | $2,468 | $534 |
| - Cash | $4 | $0 | $21 | $26 |
| + Debt | $5,413 | $5,231 | $5,154 | $4,983 |
| Enterprise Value | $10,746 | $8,100 | $7,601 | $5,491 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$208 | -$143 | -$203 | -$218 |
| % Margin | – | – | – | – |
| Net Income | -$369 | -$300 | -$348 | -$368 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.001 | -0 | -0.001 | -0.001 |
| % Growth | -50% | 20% | 16.7% | – |
| Operating Cash Flow | -$178 | -$98 | -$176 | -$127 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$178 | -$98 | -$176 | -$127 |